Literature DB >> 12605094

Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis.

Erik G Jönsson1, Lena Flyckt, Edgar Burgert, Marc-Antoine Crocq, Kaj Forslund, Marja Mattila-Evenden, Gunnar Rylander, Marie Asberg, Vishwajit L Nimgaonkar, Gunnar Edman, Lars Bjerkenstedt, Frits-Axel Wiesel, Göran C Sedvall.   

Abstract

OBJECTIVE: To further evaluate the controversial putative association between a Ser9Gly variant in the first exon of the dopamine D3 receptor gene (DRD3) and schizophrenia.
METHODS: Swedish patients with schizophrenia ( n=156) and control subjects ( n=463) were assessed for the DRD3 Ser9Gly variant. Meta-analyses including previous and the present Swedish case-control results were performed.
RESULTS: No significant difference between the Swedish patients and controls were found, but there was an association between DRD3 Ser9Gly Ser/Ser and homozygous genotypes and response to anti-psychotic drugs. This finding was supported by an incomplete meta-analysis. In a meta-analysis of all case-control studies comprising 8761 subjects the association between DRD3 Ser9Gly homozygosity and schizophrenia ( =4.96, degree of freedom=1, p <0.05, odds ratio=1.10, 95% confidence interval=1.01-1.20) persisted. However, the previously proposed association between the Ser/Ser genotype and schizophrenia was not significant (chi2 =2.71, degree of freedom=1, p>0.05, odds ratio=1.08, 95% confidence interval=0.99-1.17).
CONCLUSIONS: Whereas the present Swedish case-control analysis did not yield any evidence for association with the diagnosis, the present meta-analysis suggests that the DRD3 gene confer susceptibility to schizophrenia. Reasons for the discrepancies between prior studies are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605094     DOI: 10.1097/00041444-200303000-00001

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  19 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings.

Authors:  Thomas W Weickert; Terry E Goldberg; Michael F Egan; Jose A Apud; Martijn Meeter; Catherine E Myers; Mark A Gluck; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2010-02-20       Impact factor: 13.382

3.  Molecular epidemiology of major depressive disorder.

Authors:  Chikako Kiyohara; Kouichi Yoshimasu
Journal:  Environ Health Prev Med       Date:  2009-01-20       Impact factor: 3.674

4.  First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors.

Authors:  Steffen B Schulz; Karin E Heidmann; Arpad Mike; Zin-Juan Klaft; Uwe Heinemann; Zoltan Gerevich
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

5.  Novelty seeking mediates the effect of DRD3 variation on onset age of amphetamine dependence in Han Chinese population.

Authors:  Shin-Chang Kuo; Yi-Wei Yeh; Chun-Yen Chen; Chang-Chih Huang; Tien-Yu Chen; Che-Hung Yen; Chih-Sung Liang; Pei-Shen Ho; Ru-Band Lu; San-Yuan Huang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-27       Impact factor: 5.270

Review 6.  The genetics of schizophrenia and bipolar disorder: dissecting psychosis.

Authors:  N Craddock; M C O'Donovan; M J Owen
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

7.  Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort.

Authors:  Prachi Kukshal; Venkat Chowdari Kodavali; Vibhuti Srivastava; Joel Wood; Lora McClain; Triptish Bhatia; A M Bhagwat; Smita Neelkanth Deshpande; Vishwajit Laxmikant Nimgaonkar; B K Thelma
Journal:  J Psychiatr Res       Date:  2013-08-08       Impact factor: 4.791

8.  A network of dopaminergic gene variations implicated as risk factors for schizophrenia.

Authors:  Michael E Talkowski; George Kirov; Mikhil Bamne; Lyudmila Georgieva; Gonzalo Torres; Hader Mansour; Kodavali V Chowdari; Vihra Milanova; Joel Wood; Lora McClain; Konasale Prasad; Brian Shirts; Jianping Zhang; Michael C O'Donovan; Michael J Owen; Bernie Devlin; Vishwajit L Nimgaonkar
Journal:  Hum Mol Genet       Date:  2007-11-27       Impact factor: 6.150

Review 9.  Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples.

Authors:  Michael E Talkowski; Howard Seltman; Anne S Bassett; Linda M Brzustowicz; Xiangning Chen; Kodavali V Chowdari; David A Collier; Quirino Cordeiro; Aiden P Corvin; Smita N Deshpande; Michael F Egan; Michael Gill; Kenneth S Kendler; George Kirov; Leonard L Heston; Pat Levitt; David A Lewis; Tao Li; Karoly Mirnics; Derek W Morris; Nadine Norton; Michael C O'Donovan; Michael J Owen; Christian Richard; Prachi Semwal; Janet L Sobell; David St Clair; Richard E Straub; B K Thelma; Homero Vallada; Daniel R Weinberger; Nigel M Williams; Joel Wood; Feng Zhang; Bernie Devlin; Vishwajit L Nimgaonkar
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

10.  Genetic biomarkers of depression.

Authors:  Anand Tamatam; Farhath Khanum; Amarinder Singh Bawa
Journal:  Indian J Hum Genet       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.